Skip to content

The resistant starch in the treatment of non-alcoholic fatty liver disease, a multi-center, randomized, double blind, controlled trial

The resistant starch in the treatment of non-alcoholic fatty liver disease, a multi-center, randomized, double blind, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015722
Enrollment
Unknown
Registered
2018-04-16
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

Sponsors

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Non-alcoholic fatty liver disease dignosed by ultrasound test in recent one year; Aged 18-70 years old; Written informed consents must be obtained.

Exclusion criteria

Exclusion criteria: Subjects with diabetes mellitus;Subjects with an alcohol consumption history of more than 20 g per day for men and more than 10 g per day for women; Subjects with acute or chronic gastrointestinal diseases; Pregnant, breastfeeding women or women planning to get pregnant are excluded; Subjects suffering diseases or those who have consumed antibiotics within 3 weeks before participation in the trial; Subjects with hepatic virus infections, autoimmune liver disease, Wilsons disease, or other liver diseases will be ruled out;Subjects who have hyperthyroidism, hypothyroidism, uncontrolled hypertension, chronic kidney disease, cardiac infarction or heart failure in recent half year; Subjects prescribed with drugs or other Chinese or western medicines (except for regular contraceptives); Subjects who have used tetraiodothyronine or glucocorticoids which will influence glucose metabolism;Subjects expected to have poor compliance;Subjects who have used weight loss medication or program in the previous 3 months;

Design outcomes

Primary

MeasureTime frame
intrahepatic triglyceride content;

Secondary

MeasureTime frame
stiffness;quantitative determination of liver fat;controlled attenuation parameter;subcutaneous fat area;visceral fat area;Anthropometry;glycemic control;lipid profiles;liver enzymes;biochemical indexes;cytokines;gastrointestinal hormones;compositional alterations of gut microbiota;

Countries

China

Contacts

Public ContactWeiping Jia
wpjia@yahoo.com+86 021-24058924

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026